688105.SH
诺唯赞
SSE · Healthcare · Biotechnology · CN
CNY 22.51
−7.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4B | 1.4B | 1.4B | 1.3B | 3.6B |
| Cost of Revenue | 425.3M | 419.7M | 414.4M | 372.6M | 1.1B |
| Gross Profit | 988.2M | 958.2M | 963.5M | 913.4M | 2.5B |
| Operating Expenses | |||||
| R&D Expense | 281.9M | 280.7M | 300.4M | 338.6M | 396.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 211.3M | 214.9M | 231.3M | 236.2M | 296.6M |
| Selling & Marketing Expense | 520.3M | 509.2M | 491.5M | 472.7M | 522.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.0B | 1.0B | 1.0B | 1.0B | 1.2B |
| Cost and Expenses | 1.5B | 1.4B | 1.5B | 1.4B | 2.3B |
| Operating Income (EBIT) | (43.0M) | (39.6M) | (61.4M) | (100.2M) | 717.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (37.4M) | (37.7M) | (58.3M) | (115.7M) | 609.4M |
| Income Tax Expense | (15.1M) | (15.2M) | (38.6M) | (42.9M) | 15.9M |
| Bottom Line | |||||
| Net Income | (14.3M) | (16.6M) | (18.1M) | (71.0M) | 594.2M |
| Earnings from Cont. Ops | (22.4M) | (22.5M) | (19.6M) | (72.9M) | 593.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (14.3M) | (16.6M) | (18.1M) | (71.0M) | 594.2M |
| Per Share | |||||
| Basic EPS | (CN¥0.03) | (CN¥0.04) | (CN¥0.05) | (CN¥0.18) | CN¥1.49 |
| Diluted EPS | (CN¥0.03) | (CN¥0.04) | (CN¥0.05) | (CN¥0.18) | CN¥1.49 |
| Revenue Per Share | CN¥3.38 | CN¥3.32 | CN¥3.81 | CN¥3.26 | CN¥8.95 |
| Shares | |||||
| Basic Shares Outstanding | 418.2M | 415.3M | 361.9M | 394.2M | 398.8M |
| Diluted Shares Outstanding | 418.2M | 415.3M | 361.9M | 394.2M | 398.8M |
| Profitability Metrics | |||||
| EBITDA | — | 121.8M | 109.4M | 75.7M | 875.7M |
| D&A | — | 161.4M | 170.8M | 175.9M | 158.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026